Semaglutide weekly injection
Sponsors
Ministry of Health, Saudi Arabia, General Committee of Teaching Hospitals and Institutes, Egypt
Conditions
Morbid ObesityType 1 Diabetes
Phase 1
Phase 4
Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher
Not yet recruitingNCT07859137
Start: 2026-10-01End: 2028-11-01Target: 100Updated: 2026-10-05
Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)
Not yet recruitingNCT07859150
Start: 2026-10-01End: 2029-04-01Target: 104Updated: 2026-10-05
Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery
Not yet recruitingNCT07859189
Start: 2026-10-01End: 2028-10-01Target: 100Updated: 2026-10-05
Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery
Not yet recruitingNCT07859176
Start: 2026-10-01End: 2028-04-01Target: 100Updated: 2026-10-05
Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain
Not yet recruitingNCT07859163
Start: 2026-10-01End: 2029-04-01Target: 100Updated: 2026-10-05